The effects of Escherichia coli lipopolysaccharide (LPS) on adenylate cyclase have been tested using renal tubular membranes and renal glomeruli isolated from rats. E. Coli LPS did not stimulate glomerular and tubular basal adenylate cyclase activity whereas it was an activator in the presence of fluoride. The effect of E. Coli LPS was immediate but was greater after 20 min preincubation. Maximum stimulation of both glomerular and tubular fluoride sensitive adenylate cyclase occurred at 125 µg/ml of E. Coli LPS with an apparent Km (dose corresponding to 50% of maximum stimulation) of 30 µg/ml. Above 125 µg/ml there was a decrease in adenylate cyclase activity. E. Coli LPS produced an increase in the maximum velocity of both enzymes but did not affect their affinity for adenosine triphosphate. E. Coli LPS did not potentiate the effect of parathyroid hormone on glomerular and tubular adenylate cyclase. The lipid A moiety which is common to all LPS whatever the original strain gave results similar to those obtained with the entire LPS. This effect was specific and did not depend on the phospholipidic structure in general since no activation was obtained in the presence of phosphatidylserine.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.